U.S. Department of Health and Human Services. FDA approves first non-invasive DNA screening test for colorectal cancer. August 11, 2014. Accessed May 15, 2021. https://wayback.archive-it.org/7993/20170112222835/http:/www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409021.htm
Cologuard. Cologuard: appropriate patients. Accessed July 26, 2021. https://www.cologuardhcp.com/about/appropriate-patients
Imperiale TF, Ransohoff DF, Itzkowitz SH, et al.; Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
Olson JE, Kirsch EJ, Edwards DKV, et al.; Colorectal cancer outcomes after screening with the multi-target stool DNA assay: protocol for a large-scale, prospective cohort study (the Voyage study). BMJ Open Gastroenterol. 2020;7(1):e000353.
Davidson KW, Barry MJ, Mangione CM, et al.; Screening for colorectal cancer: US Preventive Services Task Force recommendation statement [published correction appears in JAMA. 2021;326(8):773]. JAMA. 2021;325(19):1965-1977.
Cologuard. About Cologuard: ease of use. Accessed December 20, 2021. https://www.cologuardhcp.com/about/ease-of-use
Prince M, Lester L, Chiniwala R, et al.; Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients. World J Gastroenterol. 2017;23(3):464-471.
Wolf AMD, Fontham ETH, Church TR, et al.; Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250-281.
Cotter TG, Burger KN, Devens ME, et al.; Long-term follow-up of patients having false-positive multitarget stool DNA tests after negative screening colonoscopy: the LONG-HAUL cohort study. Cancer Epidemiol Biomarkers Prev. 2017;26(4):614-621.
Geenen DJ, Imperiale TF, Caskey SL, et al.; A 3-year observational study of persons with a negative colonoscopy and positive multi-target stool DNA test. Gastroenterology. 2017;152(suppl 1):S838.
Cologuard. Why Cologuard: affordable screening. [Price provided by Cologuard representative.] Accessed July 26, 2021. https://www.cologuard.com/affordable
Subramanian S, Tangka FKL, Hoover S, et al.; Comparison of program resources required for colonoscopy and fecal screening: findings from 5 years of the Colorectal Cancer Control Program. Prev Chronic Dis. 2019;16:E50.
Healthcare Bluebook. Colonoscopy (screening). Accessed December 15, 2021 (zip code: 66211). https://www.healthcarebluebook.com/ui/proceduredetails/402
Ladabaum U, Mannalithara A. Comparative effectiveness and cost effectiveness of a multitarget stool DNA test to screen for colorectal neoplasia. Gastroenterology. 2016;151(3):427-439.e6.
Green BB, Coronado GD, Devoe JE, et al.; Navigating the murky waters of colorectal cancer screening and health reform. Am J Public Health. 2014;104(6):982-986.
Gregg K. ‘This bill will save lives’: ban on copays for colon cancer screening signed into law. The Providence Journal. Accessed August 2, 2021. https://www.providencejournal.com/story/news/politics/2021/04/29/copays-colon-cancer-screening-colonoscopies-banned-ri-law/4887820001/
Removing Barriers to Colorectal Cancer Screening Act of 2020, HR 1570, 116th Cong (2019–2021). Accessed August 2, 2021. https://www.govtrack.us/congress/bills/116/hr1570
